JP2019514877A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019514877A5 JP2019514877A5 JP2018555177A JP2018555177A JP2019514877A5 JP 2019514877 A5 JP2019514877 A5 JP 2019514877A5 JP 2018555177 A JP2018555177 A JP 2018555177A JP 2018555177 A JP2018555177 A JP 2018555177A JP 2019514877 A5 JP2019514877 A5 JP 2019514877A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound according
- linker
- alkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 4
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims description 4
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 235000013877 carbamide Nutrition 0.000 claims description 4
- 239000004202 carbamide Substances 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 150000003457 sulfones Chemical class 0.000 claims description 4
- 150000003568 thioethers Chemical class 0.000 claims description 4
- 102000015367 CRBN Human genes 0.000 claims description 2
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 claims description 2
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 claims description 2
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 claims description 2
- 230000002424 anti-apoptotic effect Effects 0.000 claims description 2
- 230000018883 protein targeting Effects 0.000 claims description 2
- 125000003368 amide group Chemical group 0.000 claims 2
- 0 *Nc(cc1)cc(C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O Chemical compound *Nc(cc1)cc(C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O 0.000 description 2
- BTODVRFBCGOZGM-UHFFFAOYSA-N CC(C)Nc(cccc1C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O Chemical compound CC(C)Nc(cccc1C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O BTODVRFBCGOZGM-UHFFFAOYSA-N 0.000 description 1
- AOAWMQJVACPFTA-UHFFFAOYSA-N CC(C)Nc(cccc1CN2C(CCC(N3)=O)C3=O)c1C2=O Chemical compound CC(C)Nc(cccc1CN2C(CCC(N3)=O)C3=O)c1C2=O AOAWMQJVACPFTA-UHFFFAOYSA-N 0.000 description 1
- KBKBMAPKDBDLGN-UHFFFAOYSA-N CC(C)Oc(cc1)cc(C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O Chemical compound CC(C)Oc(cc1)cc(C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O KBKBMAPKDBDLGN-UHFFFAOYSA-N 0.000 description 1
- SBEBGZQERFEASE-UHFFFAOYSA-N CCC(C)c(cc1C(N2C(CCC(N3)=O)C3=O)=O)ccc1C2=O Chemical compound CCC(C)c(cc1C(N2C(CCC(N3)=O)C3=O)=O)ccc1C2=O SBEBGZQERFEASE-UHFFFAOYSA-N 0.000 description 1
- FAZWECWNUTULOK-UHFFFAOYSA-N CCc1cccc(C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O Chemical compound CCc1cccc(C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O FAZWECWNUTULOK-UHFFFAOYSA-N 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N Nc1cccc2c1CN(C(CCC(N1)=O)C1=O)C2=O Chemical compound Nc1cccc2c1CN(C(CCC(N1)=O)C1=O)C2=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662325856P | 2016-04-21 | 2016-04-21 | |
| US62/325,856 | 2016-04-21 | ||
| PCT/US2017/028875 WO2017184995A1 (en) | 2016-04-21 | 2017-04-21 | Compounds that induce degradation of anti-apoptotic bcl-2 family proteins and the uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019514877A JP2019514877A (ja) | 2019-06-06 |
| JP2019514877A5 true JP2019514877A5 (enExample) | 2020-06-11 |
| JP6936498B2 JP6936498B2 (ja) | 2021-09-15 |
Family
ID=60116391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555177A Active JP6936498B2 (ja) | 2016-04-21 | 2017-04-21 | 抗アポトーシス性Ｂｃｌ−２ファミリータンパク質の分解を誘導する化合物及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10807977B2 (enExample) |
| EP (1) | EP3445452B1 (enExample) |
| JP (1) | JP6936498B2 (enExample) |
| KR (1) | KR102447884B1 (enExample) |
| CN (1) | CN109152933B (enExample) |
| AU (1) | AU2017254687B2 (enExample) |
| WO (2) | WO2017184995A1 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106456699B (zh) | 2014-05-05 | 2021-07-02 | 生物风险投资有限责任公司 | 作为抗老化剂抑制抗凋亡的Bcl-2蛋白的组合物和方法 |
| CA2955972A1 (en) | 2014-07-22 | 2016-01-28 | Bioventures, Llc. | Compositions and methods for selectively depleting senescent cells |
| CN109152933B (zh) | 2016-04-21 | 2022-12-02 | 生物风险投资有限责任公司 | 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途 |
| SI3526202T1 (sl) | 2016-10-11 | 2025-04-30 | Arvinas Operations, Inc. | Spojine in postopki za ciljno razgradnjo androgenskih receptorjev |
| MX2019005007A (es) | 2016-11-01 | 2019-07-18 | Arvinas Inc | Protac dirigidos a la proteína tau y métodos asociados de uso. |
| JP7258009B2 (ja) | 2017-07-10 | 2023-04-14 | セルジーン コーポレイション | 抗増殖化合物及びその使用方法 |
| IL316472A (en) | 2018-01-10 | 2024-12-01 | Recurium Ip Holdings Llc | Benzamide compounds |
| ES3041854T3 (en) | 2018-01-22 | 2025-11-17 | Bioventures Llc | Bcl-2 proteins degraders for cancer treatment |
| US12539292B2 (en) | 2018-04-01 | 2026-02-03 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| WO2019221755A1 (en) | 2018-05-18 | 2019-11-21 | Bioventures, Llc | Piperlongumine analogues and uses thereof |
| WO2019218904A1 (zh) * | 2018-05-18 | 2019-11-21 | 四川科伦博泰生物医药股份有限公司 | 非天然氨基酸类衍生物、其制备方法及用途 |
| MX2021000395A (es) | 2018-07-11 | 2021-05-12 | Rubedo Life Sciences Inc | Composiciones senolíticas y usos de las mismas. |
| WO2020163823A2 (en) * | 2019-02-08 | 2020-08-13 | University Of Florida Research Foundation, Incorporated | Therapeutic agents and methods of treatment |
| AU2020310147A1 (en) * | 2019-07-10 | 2022-01-06 | Recurium Ip Holdings, Llc | Bcl-2 protein inhibitors |
| EP3999182A1 (en) | 2019-07-17 | 2022-05-25 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated methods of use |
| JP7502425B2 (ja) * | 2019-10-01 | 2024-06-18 | アルヴィナス・オペレーションズ・インコーポレイテッド | Ｂｒｍ標的化化合物および関連使用方法 |
| CN112707900B (zh) * | 2019-10-24 | 2022-06-10 | 上海科技大学 | 蛋白降解剂及其在疾病治疗中的应用 |
| JP7871189B2 (ja) * | 2019-12-17 | 2026-06-08 | オリオニス バイオサイエンシズ，インコーポレイテッド | タンパク質の動員および／または分解を調節する化合物 |
| CA3163593A1 (en) * | 2020-01-15 | 2021-07-22 | Guangrong Zheng | Therapeutic agents and methods of treatment |
| CN115244051B (zh) * | 2020-03-12 | 2024-10-18 | 南京明德新药研发有限公司 | 苯并五元环类化合物 |
| CA3173843A1 (en) * | 2020-04-28 | 2021-11-04 | Recurium Ip Holdings, Llc | Bcl-2 protein inhibitors |
| CN115996918A (zh) | 2020-05-09 | 2023-04-21 | 阿尔维纳斯运营股份有限公司 | 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型 |
| CN117242060B (zh) | 2021-01-13 | 2026-07-17 | 蒙特罗莎治疗股份有限公司 | 异吲哚啉酮化合物 |
| JP2024505562A (ja) | 2021-02-02 | 2024-02-06 | レス ラボラトイレス セルビエル | 選択的ｂｃｌ－ｘｌ ｐｒｏｔａｃ化合物及び使用の方法 |
| CA3217792A1 (en) | 2021-05-07 | 2022-11-10 | Kymera Therapeutics, Inc | Cdk2 degraders and uses thereof |
| WO2022255888A1 (en) * | 2021-06-01 | 2022-12-08 | Captor Therapeutics S.A. | Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein |
| US20240408085A1 (en) * | 2021-09-01 | 2024-12-12 | Xizang Haisco Pharmaceutical Co., Ltd. | Compound for degradation of bcl-2 family proteins and medical application thereof |
| WO2023044046A1 (en) * | 2021-09-17 | 2023-03-23 | Kymera Therapeutics, Inc. | Bcl-xl degraders and uses thereof |
| KR20240109245A (ko) * | 2021-11-17 | 2024-07-10 | 히트젠 주식회사 | 분해제 및 이의 용도 |
| CN116396288B (zh) * | 2022-01-04 | 2026-04-03 | 上海科技大学 | 基于bcl-2家族蛋白配体化合物开发的蛋白降解剂及它们的应用 |
| WO2023205802A2 (en) * | 2022-04-22 | 2023-10-26 | Sens Research Foundation | Senolytic targets of senescent cells |
| AU2023264537A1 (en) | 2022-05-06 | 2024-11-14 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
| EP4519260A1 (en) | 2022-05-06 | 2025-03-12 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-xdegraders |
| PE20250007A1 (es) | 2022-05-06 | 2025-01-07 | Treeline Biosciences Inc | Degradadores bcl-xl-heterobifuncionales de tetrahidroisoquinolina |
| WO2024012449A1 (zh) * | 2022-07-12 | 2024-01-18 | 正大天晴药业集团股份有限公司 | 含有三氟甲基基团的化合物 |
| TW202415653A (zh) * | 2022-08-02 | 2024-04-16 | 大陸商北京星奇原生物科技有限公司 | Ｂｃｌ－ｘｌ降解化合物 |
| CN121974911A (zh) * | 2022-09-01 | 2026-05-05 | 上海睿跃生物科技有限公司 | 降解蛋白的化合物及其应用和药物 |
| CN119923390A (zh) * | 2022-09-06 | 2025-05-02 | 西藏海思科制药有限公司 | 一种抑制Bcl-2或Bcl-xL的化合物及其在医药上的应用 |
| CN115260191B (zh) * | 2022-09-29 | 2022-12-27 | 上海睿跃生物科技有限公司 | 哌啶类化合物及其制备方法和应用 |
| CN115286689B (zh) * | 2022-09-29 | 2023-01-06 | 上海睿跃生物科技有限公司 | 靶向降解Bcl-2蛋白的化合物及其应用和药物 |
| CN119866335A (zh) * | 2022-09-30 | 2025-04-22 | 江苏恒瑞医药股份有限公司 | 一种用于bcl-2蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用 |
| CN115286630B (zh) * | 2022-10-09 | 2022-12-27 | 上海睿跃生物科技有限公司 | 哌嗪类化合物及其制备方法和应用 |
| WO2024078581A1 (en) * | 2022-10-12 | 2024-04-18 | Appicine Therapeutics (Hk) Limited | Selective bcl-xl protac compounds and uses thereof |
| WO2024123195A1 (en) * | 2022-12-06 | 2024-06-13 | Captor Therapeutics S.A. | Targeted protein degradation using prodrugs of bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein |
| JP2025540970A (ja) * | 2022-12-06 | 2025-12-17 | キャプター セラピューティクス エス．エー． | ユビキチンリガーゼ及びターゲットｍｃｌ－１タンパク質に結合する二機能性化合物を使用するターゲティングされたタンパク質分解 |
| CN121652220A (zh) * | 2023-02-17 | 2026-03-13 | 正大天晴药业集团股份有限公司 | 含有三氟甲磺酰基的化合物 |
| WO2024245312A1 (en) * | 2023-05-30 | 2024-12-05 | Ascentage Pharma (Suzhou) Co., Ltd. | Bcl-2/bcl-xl protein degrader and use thereof |
| IL327973A (en) | 2023-11-07 | 2026-06-01 | Treeline Biosciences Inc | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
| KR20260111020A (ko) | 2023-11-07 | 2026-07-14 | 트리라인 바이오사이언시스, 인크. | 테트라히드로이소퀴놀린 이종이작용성 bcl-xl 분해제 |
| AU2024378690A1 (en) | 2023-11-07 | 2026-05-07 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-x l degraders |
| IL328585A (en) * | 2023-11-27 | 2026-07-01 | Rubedo Life Sciences Inc | Phosphorus-containing BCL inhibitors and senolytic compounds and uses thereof |
| AU2024392985A1 (en) | 2023-12-08 | 2026-06-04 | Arvinas Operations, Inc. | Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy |
| WO2025136208A1 (en) | 2023-12-21 | 2025-06-26 | Hadjab Saida | Senolytic compounds for use in the treatment and/or prevention of a headache disorder and/or chronic pain |
| CN117624134B (zh) * | 2024-01-26 | 2024-05-03 | 南昌市第一医院 | 一种靶向降解hdac4的化合物及其制备方法和应用 |
| CN118908940B (zh) * | 2024-10-11 | 2024-12-31 | 齐鲁理工学院 | 一种靶向抗凋亡Bcl-2的蛋白水解靶向嵌合体的制备和应用 |
| WO2026114258A1 (en) * | 2024-11-27 | 2026-06-04 | Ascentage Pharma (Suzhou) Co., Ltd. | Bcl-2/bcl-xl protein degrader and use thereof |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
| US4529561A (en) | 1978-03-24 | 1985-07-16 | The Regents Of The University Of California | Method for producing liposomes in selected size range |
| US4241046A (en) | 1978-11-30 | 1980-12-23 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4925661A (en) | 1984-04-19 | 1990-05-15 | Leaf Huang | Target-specific cytotoxic liposomes |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| US4755388A (en) | 1984-11-09 | 1988-07-05 | The Regents Of The University Of California | Liposome-encapsulated 5-fluoropyrimidines and methods for their use |
| DE3542773A1 (de) | 1985-12-04 | 1987-06-11 | Roehm Pharma Gmbh | Hautwirksame pharmaka mit liposomen als wirkstofftraeger |
| US4828837A (en) | 1987-03-30 | 1989-05-09 | Liposome Technology, Inc. | Non-crystalline minoxidil composition, its production and application |
| US5077211A (en) | 1988-07-06 | 1991-12-31 | Applied Genetics, Inc. | Purification and administration of dna repair enzymes |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5043164A (en) | 1989-01-17 | 1991-08-27 | The University Of Tennessee Research Corporation | Blood-stable, cholesterol-free liposomes |
| US5064655A (en) | 1989-02-24 | 1991-11-12 | Liposome Technology, Inc. | Liposome gel composition and method |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| EP0532767B1 (en) | 1991-04-05 | 1997-03-05 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | 3-Phenoxybenzyl(idene)pyrrolidine derivatives, their preparation and their use as muscarinic cholinergic agents |
| US5491069A (en) | 1994-02-18 | 1996-02-13 | The Regents Of The University Of California | Biomarkers of cell senescence |
| US5888764A (en) | 1995-01-20 | 1999-03-30 | Uab Research Foundation | Human fas gene promoter region |
| DE19713393C2 (de) | 1997-04-01 | 2002-12-05 | Apotech Res & Dev Ltd | Flip-Gen und Flip-Protein |
| JPH11349568A (ja) | 1998-06-08 | 1999-12-21 | Maruho Co Ltd | ラクタム誘導体及びその医薬用途 |
| CA2338328A1 (en) | 1998-07-21 | 2000-02-03 | Thomas Jefferson University | Small molecule inhibitors of bcl-2 proteins |
| AUPR038200A0 (en) | 2000-09-26 | 2000-10-19 | Beta Peptide Foundation Pty Ltd, The | Compositions and methods for delaying, preventing, rejuvenating or reversing senescence |
| ATE474568T1 (de) | 2001-05-30 | 2010-08-15 | Univ Michigan | Synergistische kombination von (-) -gossypol mit docetaxel oder paclitaxel zur behandlung von krebs. |
| ATE345504T1 (de) | 2002-05-07 | 2006-12-15 | Pasteur Institut | Screeningverfahren für peptide, die die bindung von pp1c an bcl-2, bcl-xl und bcl-w proteine inhibieren |
| WO2004066915A2 (en) | 2003-01-23 | 2004-08-12 | The Trustees Of Columbia University In The City Of New York | Old-35, a gene associated with senescence and terminal cell differentiation, and uses thereof |
| ES2382377T3 (es) | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
| US20050208151A1 (en) | 2003-10-30 | 2005-09-22 | Entelos, Inc. | Treatment of rheumatoid arthritis with FLIP antagonists |
| US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| EP1692486B1 (en) | 2003-12-12 | 2015-10-28 | Saint Louis University | Biosensors for detecting macromolecules and other analytes |
| EP2261218B1 (en) | 2004-05-26 | 2013-04-03 | Eisai R&D Management Co., Ltd. | Imidazole compound for use as an intermediate in the production of cinnamide compounds |
| BRPI0514504A (pt) | 2004-08-20 | 2008-06-10 | Univ Michigan | pequenas moléculas inibidoras de membros da famìlia bcl-2 anti-apoptóticos e os usos das mesmas |
| ES2493466T3 (es) | 2005-05-12 | 2014-09-11 | Abbvie Bahamas Ltd. | Promotores de la apoptosis |
| EP2135078B1 (en) | 2007-03-09 | 2013-08-21 | DiscoveRx Corporation | Methods for identifying agents and their use for the prevention or stabilization of fibrosis |
| BRPI0810082A2 (pt) | 2007-03-29 | 2014-10-21 | Novartis Ag | 3-imidazolil-indóis para o tratamento de doenças proliferativas |
| US20100310504A1 (en) | 2007-09-26 | 2010-12-09 | Lowe Scott W | Methods for treating fibrosis by modulating cellular senescence |
| US20120156134A1 (en) | 2007-12-20 | 2012-06-21 | Shayne Squires | Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease |
| US20090312373A1 (en) | 2008-03-11 | 2009-12-17 | The General Hospital Corporation | Methods for the treatment of cancer using piperlongumine and piperlongumine analogs |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| US20100086941A1 (en) | 2008-10-01 | 2010-04-08 | Adami Guy R | Methods for determining aged based accumulation of senescent cells using senescence specific DNA damage markers |
| KR101685718B1 (ko) | 2008-12-19 | 2016-12-12 | 제넨테크, 인크. | 헤테로시클릭 화합물 및 사용 방법 |
| EP2376085B1 (en) | 2008-12-19 | 2014-02-26 | Genentech, Inc. | Compounds and methods of use |
| BRPI1016102A2 (pt) | 2009-04-15 | 2015-09-01 | Sanford Burhnham Medical Res Inst | Inibidores de proteínas anti-apoptótica baseados em naftaleno |
| ES2546294T7 (es) * | 2009-05-26 | 2024-06-06 | Abbvie Ireland Unlimited Co | Agentes inductores de la apoptosis para el tratamiento de cáncer y enfermedades inmunitarias y autoinmunitarias |
| EP2289528A1 (en) | 2009-07-21 | 2011-03-02 | DSM IP Assets B.V. | Novel nutraceutical compositions containing black pepper or its constituents improving mental performance |
| US20120157455A1 (en) | 2009-09-02 | 2012-06-21 | Canthera Therapeutics, Inc. | Compounds And Compositions For Treating Cancer |
| US8318737B2 (en) | 2009-09-02 | 2012-11-27 | Canthera Therapeutics Inc. | Compounds and compositions for treating cancer |
| US8349832B2 (en) | 2009-09-02 | 2013-01-08 | Canthera Therapeutics | Compounds and compositions for treating cancer |
| EP2519260A2 (en) | 2009-12-31 | 2012-11-07 | Deutsches Krebsforschungszentrum | Novel modulators of trail signalling |
| CN101774875A (zh) | 2010-01-08 | 2010-07-14 | 北京欧凯纳斯科技有限公司 | 一种荜拔酰胺类化合物的合成方法 |
| CN102125552A (zh) | 2010-01-20 | 2011-07-20 | 李绍路 | 荜茇酰胺衍生物在制备治疗癌症的药物中的用途及其药物组合物 |
| CN102146054A (zh) | 2010-02-10 | 2011-08-10 | 新昌县来益科技开发有限公司 | 荜茇酰胺衍生物及其药物组合物和在制备抑制肿瘤生长的药物中的用途 |
| WO2011130395A1 (en) | 2010-04-13 | 2011-10-20 | University Of Utah Research Foundation | Inhibitors of flip to treat cancer |
| RU2593231C2 (ru) * | 2010-11-23 | 2016-08-10 | ЭббВи Айэленд Анлимитед Компани | Способы лечения с использованием селективных ингибиторов bcl-2 |
| KR101762724B1 (ko) * | 2011-01-25 | 2017-07-28 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | Bcl-2/bcl-xl 억제제 및 이를 이용한 치료 방법 |
| CN103958508B (zh) * | 2011-10-14 | 2019-02-12 | 艾伯维公司 | 用于治疗癌症以及免疫与自身免疫性疾病的细胞凋亡诱导剂 |
| EP2602330A1 (en) | 2011-12-07 | 2013-06-12 | Palacky University, Olomouc | Method of determination of cancer cell drug sensitivity towards Aurora kinase inhibitors and overcoming their resistance |
| KR102438072B1 (ko) * | 2012-01-12 | 2022-08-31 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| WO2013178821A1 (en) | 2012-06-01 | 2013-12-05 | Leibniz-Institut für Altersforschung - Fritz-Lipmann-Institut e.V. (FLI) | Inhibitors of the notch signalling pathway and secretion for use in medicine |
| US9108923B2 (en) | 2012-07-20 | 2015-08-18 | Howard Hughes Medical Institute | Compounds, compositions, and methods for cancer therapy |
| CN103601670B (zh) | 2012-11-20 | 2016-06-15 | 中国人民解放军第二军医大学 | 荜拔酰胺类似物及其制备方法与应用 |
| US10279018B2 (en) | 2012-12-03 | 2019-05-07 | Unity Biotechnology, Inc. | Immunogenic compositions for inducing an immune response for elimination of senescent cells |
| GB201311910D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel Compounds |
| EP2945940B1 (en) | 2013-01-16 | 2020-07-15 | The Regents of The University of Michigan | Bcl-2/bcl-xl inhibitors and their use in the treatment of cancer |
| BR112015026702A2 (pt) | 2013-04-21 | 2018-02-06 | Yeda Res And Developmente Co Ltd | métodos de extermínio de células senescentes |
| US9993472B2 (en) * | 2014-01-28 | 2018-06-12 | Unity Biotechnology, Inc. | Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2 |
| EP4649963A3 (en) * | 2014-04-14 | 2026-05-13 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| CN106456699B (zh) | 2014-05-05 | 2021-07-02 | 生物风险投资有限责任公司 | 作为抗老化剂抑制抗凋亡的Bcl-2蛋白的组合物和方法 |
| CA2955972A1 (en) | 2014-07-22 | 2016-01-28 | Bioventures, Llc. | Compositions and methods for selectively depleting senescent cells |
| US10071164B2 (en) | 2014-08-11 | 2018-09-11 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| US20180021323A1 (en) | 2015-01-22 | 2018-01-25 | Bioventures, Llc | Flip - a selective molecular target of senescent cells |
| WO2016118855A1 (en) | 2015-01-22 | 2016-07-28 | Board Of Trustees Of The University Of Arkansas | Compositions and methods for selectively depleting senescent cells comprising death receptors |
| US20180000816A1 (en) * | 2015-02-06 | 2018-01-04 | Unity Biotechnology, Inc. | Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions |
| AU2016232705C1 (en) * | 2015-03-18 | 2021-06-17 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| CN105085620B (zh) | 2015-06-25 | 2018-05-08 | 中山大学附属第一医院 | 一种靶向泛素化降解Smad3的化合物 |
| US11179348B2 (en) | 2015-07-21 | 2021-11-23 | Fundación Universidad Católica De Valencia San Vicente Mártir | Combination comprising pterostilbene for the treatment of cancer |
| EP3337476A4 (en) * | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| US11111259B2 (en) | 2015-12-18 | 2021-09-07 | Unity Biotechnology, Inc. | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders |
| US20190054097A1 (en) | 2016-04-21 | 2019-02-21 | Bioventures, Llc | Compositions targeting senescent cells and the uses thereof |
| CN109152933B (zh) | 2016-04-21 | 2022-12-02 | 生物风险投资有限责任公司 | 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途 |
| ES3041854T3 (en) * | 2018-01-22 | 2025-11-17 | Bioventures Llc | Bcl-2 proteins degraders for cancer treatment |
-
2017
- 2017-04-21 CN CN201780024822.5A patent/CN109152933B/zh active Active
- 2017-04-21 US US16/095,260 patent/US10807977B2/en active Active
- 2017-04-21 WO PCT/US2017/028875 patent/WO2017184995A1/en not_active Ceased
- 2017-04-21 JP JP2018555177A patent/JP6936498B2/ja active Active
- 2017-04-21 EP EP17786729.8A patent/EP3445452B1/en active Active
- 2017-04-21 AU AU2017254687A patent/AU2017254687B2/en active Active
- 2017-04-21 KR KR1020187029999A patent/KR102447884B1/ko active Active
-
2019
- 2019-10-17 WO PCT/US2019/056837 patent/WO2020081880A1/en not_active Ceased
-
2020
- 2020-07-03 US US16/920,649 patent/US11319316B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022547716A5 (enExample) | ||
| JP2015518831A5 (enExample) | ||
| RU2016134258A (ru) | Конъюгат лекарственного средства с направляющей молекулой и двумя различными лекарственными средствами | |
| JP2018024670A5 (enExample) | ||
| CY1124728T1 (el) | Παραγωγα βενζοξαβορολης για τη θεραπεια βακτηριακων λοιμωξεων | |
| JP2017048194A5 (enExample) | ||
| EP3821011A4 (en) | TRANSPOSOME-ACTIVATED DNA/RNA SEQUENCING (TED RNA-SEQ) | |
| LT3571224T (lt) | Patobulintos serumo albumino rišamosios medžiagos | |
| CN111601791A (zh) | Ezh2抑制剂及其药学上可接受的盐和多晶型物及其应用 | |
| JP2014520120A5 (enExample) | ||
| CY1117929T1 (el) | Παραγωγα σουλφοναμιδιου ως bcl-2-εκλεκτικοι παραγοντες διεγερσης αποπτωσης για τη θεραπεια καρκινου και ανοσοασθενειων | |
| JP2019524645A5 (enExample) | ||
| JP2015522045A5 (enExample) | ||
| EP2124555A4 (en) | NUCLEOSIDARYLPHOSPHORAMIDATE FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRUS INFECTIONS | |
| EP2560476A4 (en) | COMBINATIONS WITH CRY34AB / 35AB AND CRY3AA PROTEINS TO PREVENT THE DEVELOPMENT OF RESISTANCE IN CORAL ROOT DRILLS (DIABROTICA SPP.) | |
| EP3521430A4 (en) | DOUBLE-STRANDED NUCLEIC ACID COMPLEX WITH OVERHEAD | |
| EP3917542A4 (en) | MULTISPECIFIC BINDING PROTEINS | |
| JP2017528117A5 (enExample) | ||
| JP2013047244A5 (enExample) | ||
| EP3816290A4 (en) | ANTIBODY BINDING TO THE CELL ADHESION MOLECULE 3 | |
| MA52545A (fr) | Anticorps pour radionucléides chélatés | |
| RU2018104310A (ru) | Азотсодержащие гетероциклы в качестве пестицидов | |
| JP2010520851A5 (enExample) | ||
| EP3708667A4 (en) | IMMUNOGLOBULIN BINDING PROTEINS | |
| EP3914608A4 (en) | NOVEL INSECT CONTROL PROTEINS |